Protease inhibitors: the current status.
Dauer
Brenda
B
HIV Outpatient and Research Center, J.W. Goethe-Universität, Zentrum der Inneren Medizin, Frankfurt am Main, Germany.
D000818:Animals; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000069454:Darunavir; D003967:Diarrhea / Q000209:etiology; D004244:Dizziness / Q000209:etiology; D004353:Drug Evaluation, Preclinical / Q000639:trends; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D006261:Headache / Q000209:etiology; D006801:Humans; D011725:Pyridines / Q000493:pharmacokinetics / Q000627:therapeutic use; D011753:Pyrones / Q000493:pharmacokinetics / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011753:Pyrones; D013449:Sulfonamides; D000069454:Darunavir; C107201:tipranavir